Richard Mulligan

Richard C. Mulligan, PhD, is Head of SanaX at Sana Biotechnology. He is also the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School and visiting scientist at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).

Most recently, Richard served as Portfolio Manager at Icahn Capital. Prior to that, he was Founding Partner and Senior Managing Director of Sarissa Capital Management. After receiving postdoctoral training at the Center for Cancer Research at MIT, he joined the MIT faculty and was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Harvard and Children’s Hospital. His honors include the MacArthur Foundation ‘Genius’ Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award and the Nagai Foundation International Prize.

He earned his B.S. from MIT and his PhD from the Department of Biochemistry at Stanford University School of Medicine.